Amneal (AMRX) Q1 2026 Earnings Transcript

Amneal announced a transformative agreement to acquire Kashiv BioSciences for $750 million upfront, plus up to $350 million in milestones, 8% equity dilution and 12 years of royalties, creating a vertically integrated biosimilars platform with 20-plus programs. Q1 FY2026 results were also strong, with net revenue up 4% to $723 million, adjusted EBITDA up 19% to $202 million, and adjusted EPS up 29% to $0.27, while management raised 2026 guidance and projected 2030 biosimilar revenue of $1.0 billion-$1.3 billion. Gross margin improved roughly 500 bps year over year, leverage fell to 3.5x EBITDA, and the company outlined 2027 EBITDA of $820 million and a 2028 deleveraging path to 3x or lower.

Analysis

AMRX is trying to re-rate from a serial execution story into a platform compounder, but the market will only pay up if it believes the integration is more additive than distracting. The key second-order effect is that vertical integration turns biosimilars from a low-visibility royalty stream into a controllable margin stack: development, manufacturing, and commercialization are now all captured in-house, so every successful launch should have a much steeper operating leverage profile than a licensed model. That said, this also shifts the company’s risk from financial engineering to execution density—launch cadence, FDA timing, and manufacturing yield now matter more than headline pipeline breadth.

The near-term setup is asymmetric because the market still likely underestimates how much of 2027/2028 performance is already “pre-funded” by the base business. The core retail/adhesive/specialty mix is improving gross margin before biosimilars even contribute meaningfully, which creates a lower hurdle for the deal to look accretive by the time the first wave of approvals lands. The real inflection is not the transaction itself, but whether the company can convert the Q3/YE26 regulatory events into a credible 2-3 product commercialization engine; if that happens, the revenue mix shift by 2030 becomes far less speculative than it looks today.

The contrarian risk is that investors may over-focus on the stated long-term revenue build and underweight the capital intensity and patience required to get there. A 3.5x-3.7x leverage frame leaves less flexibility than the narrative implies if integration slips or if one of the anchor launches gets delayed. The biosimilar market may also be more competitive at the blockbuster end than management suggests, which means AMRX’s best path to upside is probably through niche, lower-competition assets where scale and execution beat branding rather than through the most crowded LOEs.

Key Decisions for Investors

• Long AMRX on a 3-6 month horizon into Q3 lanreotide/FY26 XOLAIR catalysts; upside comes from multiple approval events plus margin expansion, but trim if leverage stalls above ~3.7x or launch timing slips.
• Buy AMRX call spreads for 2027-2028 expiry rather than stock if seeking upside to the biosimilar re-rating; the risk/reward is better if the market begins to price the 2030 mix shift before cash flow fully matures.
• Pair trade: long AMRX / short a higher-multiple biosimilar pure play with less vertical integration and weaker commercial infrastructure; AMRX has a clearer path to capturing full economics if execution remains intact.
• Use any post-deal strength to hedge with a short-dated put spread on AMRX ahead of regulatory windows; this protects against approval delays without paying for full downside convexity.